Twiddy-R-R-Dr near Pick ON (946 Result(s))

ITAC is the voice of the Canadian information and communications technologies (ICT) industry which is comprised of about 33,300 companies, generates $155 billion in revenues, contributes $67.2 billion to the Canadian GDP, accounts for 3% of total employment (approximately 572,700 jobs) and is the largest performer of private sector R&D ($4.8 billion). ITAC is a prominent advocate for the expansion of Canada's innovative capacity and for stronger productivity across all sectors through the strategic use of technology. As a not-for-profit, membership-driven organization, it relies on its members for 100% of its funding. Membership is available open to all companies and organizations in Canada that are involved in ICT and fees are structured according to the size and nature of the enterprise.

ARRI Australia further expands 16mm Format into TV new ABC TV Drama Series 'East of Everything'

The Mehfil Media Group Founded by Jaswinder Sing Khosa in 1991. Jaswinder Singh Khosa an Indian media baron in canada, is the head of Mehfil Media Group. He Owns the Punjab newspaper Mehfil Khabarsar along with a MehfilTV channel in Punjab language. The Mehfil Media group has also diversified into TV------------Mehfil TV Radio---------Mehfil Radio Entertainment-R K Entertainment

Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world's largest pharmaceutical companies, with a shared commitment to improving the lives of patients.We've kept our roots in the Boston area: our headquarters, Genzyme Center, is located in Cambridge, Massachusetts, home to venerable universities, teaching hospitals, and a thriving biotechnology community. But we also operate in every other region of the globe.

We are engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Controlled-release means releasing a drug into the bloodstream or at a target site in the body, over an extended period of time or at predetermined times. In some circumstances, controlled-release drug delivery can enhance efficacy and patient compliance as compared to immediate release formats for the same drug.Our proprietary Hypermatrix™ technology is at the core of our controlled-release drug delivery approach. The flexibility of the Hypermatrix™ technology allows for the intelligent and efficient design of drugs through the precise control of a number of key variables. This allows us to respond to varying drug attributes and patient requirements, producing a desired controlled-release effect in a time and cost-effective manner.